Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.
Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.
ImClone Protocol Generates More Questions Than Answers.
Phase III Trial Would Give Clearer Picture Of C225 Role.
Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.
Levine Leaves Presidency Of Rockefeller University.
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally









